Evidence map›Paper›PMID 34988934›Full record

Observational studyEndocrine2022

Proteolytic activation of anti-Müllerian hormone is suppressed in adolescent girls.

Michael W Pankhurst, Peter W Dillingham, Alexia S Peña

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Michael W PankhurstDepartment of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.ORCID http://orcid.org/0000-0002-0976-5742
Peter W DillinghamDepartment of Mathematics and Statistics, University of Otago, Dunedin, New Zealand.
Alexia S PeñaDiscipline of Paediatrics, The University of Adelaide Robinson Research Institute, Adelaide, SA, Australia. alexia.pena@adelaide.edu.au.
University of Otago · NZWomen's and Children's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe ratio of the anti-Müllerian hormone (AMH) precursor (proAMH) to active AMH (AMH

methodsTotal AMH and proAMH were measured by immunoassay in a single-centre, cross-sectional observational study; 61 controls and 29 girls with PCOS were included in the study (age range 8-21 years). The API was calculated as proAMH as a percentage of total AMH. Differences in API between control and PCOS subjects and across age-groups were examined by Welch's ANOVA. The relationship between API and a range of metabolic parameters was examined by Pearson correlation.

resultsThe API in healthy females increased between the ages of 10~15 years and declined from 15~20 years (p < 0.001). The API was negatively correlated with body mass index in the control (p = 0.04) and PCOS groups (p = 0.007). The API was associated with factors related to adiposity and lipid metabolism. The API was not significantly different in control girls and girls with PCOS.

conclusionsHigher API during adolescence suggests that proteolytic activation of proAMH is suppressed during this life stage. API was not different between control girls and girls with PCOS indicating that it is not useful in diagnosis of PCOS during adolescence.

Indexed as

Peptide HormonesPolycystic Ovary SyndromeAdolescentAdultAnti-Mullerian HormoneBiomarkersBody Mass IndexChildCross-Sectional StudiesFemaleHumansTransforming Growth Factor betaYoung AdultAnti-Mullerian HormoneBiomarkersPeptide HormonesTransforming Growth Factor betaAdolescenceOvaryPCOSproAMHPuberty

Identifiers

PMID34988934
OpenAlexW4206426288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.